Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget’s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget’s disease patients
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03846-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jiawen Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Paget Disease, Extramammary, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Clinical Research Center for CANCER, Provincial Key R&D Program of Zhejiang Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Medical Oncology, Zhuji People's Hospital of Zhejiang province, Shaoxing, Zhejiang Province, China.
- Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zhuning2017@zju.edu.cn.
- Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zhuning2017@zju.edu.cn.
- Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. yuanying1999@zju.edu.cn.
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Clinical Research Center for CANCER
- Provincial Key R&D Program of Zhejiang Province
Zitieren
APA
Yang, J., Chen, Y., Zhang, X., Tong, Z., Weng, S., Zhu, N., & Yuan, Y. (2024). Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget’s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget’s disease patients. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03846-8
Vancouver
Yang J, Chen Y, Zhang X, Tong Z, Weng S, Zhu N, et al. Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget’s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget’s disease patients. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03846-8
BibTeX
@article{Yang2024,
author = {Yang, Jiawen and Chen, Yurong and Zhang, Xiuyuan and Tong, Ziyan and Weng, Shanshan and Zhu, Ning and Yuan, Ying},
title = {Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget’s disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget’s disease patients},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03846-8}
}
EUVIMED